In spite of spectacular advances in the treatment of acute coronary syndromes in the past few years, they are still characterized by a high mortality which in real life is more than 10% at 6 months. This joint Symposium between the ESC and AHA provided an update on the most recent studies on the mechanisms responsible for acute coronary syndromes and on new potential targets for the anti-thrombotic and anti-inflammatory treatments.
Pullback during angio to generate Chemogram
Inflammation regulates the fragility of the fibrous cap, as well as the thrombogenic potential of the plaque.
Main features of inflammation associated with ACS:
Nonspecific anti-inflammatory drugs
Specific antagonists of key cytokines
Della Bona R. Curr Pharm Des 2011;17:4172-89
As noted in the diagram, some patients may benefit from a larger relative contribution of antiplatelet therapy while others may need more anticoagulant therapy. The relative needs in individual patients may also change as time progresses after their ACS event.
From bench to practice: pathogenesis and treatment of acute coronary syndromes
Our mission: To reduce the burden of cardiovascular disease
© 2017 European Society of Cardiology. All rights reserved